A novel ‘universal’ vaccine has been engineered to provide protection from thousands of variants in one single dose. 

Results from a first-in-human clinical trial, published in the Journal of Infection, show the vaccine protected participants from multiple Sarbeco coronaviruses, a large group of viruses including SARS-CoV-2, as well as from related bat viruses that could cause future pandemics.  

The vaccine technology, harnessed by the University of Cambridge and spin-out DIOSynVax (DVX) to develop the vaccine, uses an AI-designed ‘super-antigen’ to provide lasting protection against a broad range of viruses, even as they mutate. The technology also reduces the need for frequent reformulation, which is a fundamental limitation of current vaccines. 

The vaccine was given to volunteers between 18 and 50 years old at the NIHR Southampton Clinical Research Facility at UHSFT, and at the NIHR Cambridge Clinical research Facility at Addenbrooke’s Hospital, Cambridge.

The vaccine was administered via a needle-free delivery method, which could make vaccination faster and easier to carry out in large numbers of people, especially in settings where conventional injections are more challenging to deliver. 

“We’ve converted vaccine development from being reactive to being future proof,” said Professor Jonathan Heeney from the Lab of Viral Zoonotics, University of Cambridge’s Department of Veterinary Medicine, the scientific lead of the research. 

“Our vaccines will continue to provide protection against viruses even as they mutate into new strains. 

“We’ve overcome the problem of traditional vaccines, which have limited protection. It means we can escape the constant cycle of chasing the virus variants circulating in humans and updating the vaccines to try to catch up, like a dog chasing its tail.” 

Researchers have stressed further development of the vaccine is needed before it is ready for public use, but a larger Phase II trial will next assess the vaccine’s ability to induce immune responses in a wider and more diverse population.